A Multicentre, Open-label, Three-arm Randomised Phase II Trial Assessing the Safety and Efficacy of the HSP90 Inhibitor Ganetespib in Combination With Carboplatin Followed by Maintenance Treatment With Niraparib Versus Ganetespib Plus Carboplatin Followed by Ganetespib and Niraparib Versus Carboplatin in Combination With Standard Chemotherapy Followed by Niraparib Maintenance Treatment in Platinum-sensitive Ovarian Cancer Patients

This study will be performed in women with platinum-sensitive, high-grade serous, high-grade endometrioid, undifferentiated epithelial ovarian cancer, carcinosarcoma, fallopian tube or primary peritoneal cancer (proven by central histo-pathological review).
A total of 120 subjects will be randomized (1:1:1) to three different treatment arms: (A) Standard arm (arm A): Carboplatin (AUC5 d1, q3w i.v.) in combination with Paclitaxel (175 mg/m² d1, q3w i.v.) or Carboplatin (AUC4 d1, q3w i.v.) in combination with Gemcitabine (1000 mg/m² d1, d8, q3w i.v.) followed by maintenance therapy with Niraparib (200/ 300 mg oral daily, q4w) // (B) First experimental arm (arm B): Ganetespib (150 mg/m2, d1, q3w) in combination with Carboplatin (AUC5 d1, q3w i.v.) followed by maintenance treatment with Niraparib (200/ 300 mg oral daily, q4w) // (C) Second experimental arm (arm C): Ganetespib (150 mg/m² d1, q3w i.v.) plus Carboplatin (AUC5 d1, q3w i.v.) followed by Ganetespib (100 mg/m² d1, d8, d15, d22, q4w i.v.) and Niraparib (200 mg oral daily, q4w).
Chemotherapy treatment will be given for 6 cycles, maintenance treatment with Ganetespib will be given for a maximum of 9 months or until disease progression, maintenance treatment with Niraparib can continue until disease progression.

Start Date30 Nov 2018

Sponsor / Collaborator

Universitaire Ziekenhuizen Leuven

NCT02637375 / WithdrawnNot ApplicableIIT

A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer

Based on preclinical data implicating GR, AR, and JAK/STAT activation as potent mechanisms of breast cancer cell survival despite chemotherapy administration (i.e. chemotherapy resistance), the study will test a novel approach for improving chemotherapy effectiveness by adding Hsp90 inhibition to antagonize the anti-apoptotic signaling pathways that are initiated via GR, AR, and JAK/STAT activation.

Start Date01 May 2016

Sponsor / Collaborator

The University of Chicago

NCT02389751 / CompletedPhase 1IIT

GUARDIAN-1 Trial: A Phase 1 Study of Ganetespib in Combination With Chemoradiation for Stage II-III Esophageal Carcinoma

This phase I trial studies the side effects and best dose of ganetespib when given together with paclitaxel, carboplatin, and radiation therapy in treating patients with stage II-III esophageal cancer. Ganetespib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving ganetespib in combination with paclitaxel, carboplatin, and radiation therapy may be a better treatment for patients with esophageal cancer.

Start Date10 Apr 2015

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

[+1]

100 Clinical Results associated with Ganetespib

100 Translational Medicine associated with Ganetespib

100 Patents (Medical) associated with Ganetespib

175

Literatures (Medical) associated with Ganetespib

01 Jan 2025·JOURNAL OF LIPID RESEARCH

Hsp90α promotes lipogenesis by stabilizing FASN and promoting FASN transcription via LXRα in hepatocellular carcinoma

Article

Author: Wu, Yingxia ; Cen, Shengpei ; Li, Jieyou ; Su, Hairou ; Liang, Manfeng ; Zhou, Zhifeng ; Huang, Yaling ; Zou, Fei ; Liu, Yilin ; Zheng, Zhenming ; Chen, Yukui ; Deng, Zihao ; Chen, Xuemei ; Wu, Guibing ; Liao, Yandan ; Zhang, Jinxin ; Deng, Yaotang ; Shi, Xiongjie ; Li, Yan ; Liu, Lixia ; Tan, Wenchong ; Xie, Guantai

Excessive lipid accumulation promotes the occurrence and progression of hepatocellular carcinoma (HCC), accompanied by high levels of fatty acid synthetase (FASN) and more active lipogenesis. Heat shock protein 90 (Hsp90) acts as a chaperone to maintain the stability and activity of the client proteins. Studies have revealed that Hsp90 regulates the lipid metabolism of HCC, but the effect of Hsp90 on FASN still remains unknown. This study aims to discover the mechanism of Hsp90 inhibition on lipid accumulation and investigate the different effects of Hsp90 N-terminal domain inhibitor STA9090 and C-terminal domain inhibitor novobiocin on FASN protein stability and transcription pathway in HCC. We found that HCC cells tended to store lipids, which could be disrupted by Hsp90 inhibitors in vivo and in vitro. High levels of Hsp90α and FASN in tumor tissue had correlation with poor prognosis of HCC patients, and Hsp90α interacted with FASN to maintain its protein stability. Furthermore, N-terminal domain of Hsp90α was essential for process of sterol regulatory element binding protein 1 to activate FASN transcription and Hsp90α prevented proteasomal degradation of liver X receptor α to upregulate FASN transcription via liver X receptor α/sterol regulatory element binding protein 1 axis. Our data reveal that Hsp90α promotes lipid accumulation by increasing the protein stability and FASN mRNA transcription, and can be alleviated by Hsp90 inhibitors, which provides a theoretical basis for Hsp90-targeted therapy on lipid metabolism in HCC.

01 Nov 2024·Infectious disorders drug targets

An Insight into the Repurposing of Phytoconstituents obtained from Delhi’s Aravalli Biodiversity Park as Antifungal Agents

Article

Author: Sharma, Kalicharan ; Aggarwal, Geeta ; Kaur, Amanpreet ; Sharma, Neetika

Abstract::

The global prevalence of fungal infections is alarming in both the pre- and postCOVID period. Due to a limited number of antifungal drugs, there are hurdles in treatment strategies for fungal infections due to toxic potential, drug interactions, and the development of fungal resistance. All the antifungal targets (existing and newer) and pipeline molecules showing promise against these targets are reviewed. The objective was to predict or repurpose phyto-based antifungal compounds based on a dual target inhibition approach (Sterol-14-αdemethylase and HSP-90) using a case study. In pursuit of repurposing the phytochemicals as antifungal agents, a team of researchers visited Aravalli Biodiversity Park (ABP), Delhi, India, to collect information on available medicinal plants. From 45 plants, a total of 1149 ligands were collected, and virtual screening was performed using Schrodinger Suite 2016 software to get 83 hits against both the target proteins: Sterol-14-α-demethylase and HSP-90. After analysis of docking results, ligands were selected based on their interaction against both the target proteins and comparison with respective standard ligands (fluconazole and ganetespib). We have selected Isocarthamidin, Quercetin and Boeravinone B based on their docking score and binding interaction against the HSP-90 (Docking Score -9.65, -9.22 and -9.21, respectively) and 14-α-demethylase (Docking Score -9.19, -10.76 and -9.74 respectively). The docking protocol was validated and MM/GBSA studies depicted better stability of selected three ligands (Isocarthamidin, Quercetin, Boeravinone B) complex as compared to standard complex. Further, MD simulation studies were performed using the Desmond (67) software package version 2018-4. All the findings are presented as a case study for the prediction of dual targets for the repurposing of certain phytochemicals as antifungal agents.

15 Sep 2024·International journal of cancer

Gene expression markers in peripheral blood and outcome in patients with platinum‐resistant ovarian cancer: A study of the European GANNET53 consortium

Article

Author: Mahner, Sven ; Concin, Nicole ; Wimberger, Pauline ; Mohr, Thomas ; Pujade‐Lauraine, Eric ; Vergote, Ignace ; Obermayr, Eva ; Joly‐Lobbedez, Florence ; Harter, Philipp ; Sehouli, Jalid ; Ray‐Coquard, Isabelle ; Zeillinger, Robert ; Taube, Eliane ; Schuster, Eva ; Moll, Ute Martha ; Braicu, Elena Ioana

Abstract:

Disease progression is a major problem in ovarian cancer. There are very few treatment options for patients with platinum‐resistant ovarian cancer (PROC), and therefore, these patients have a particularly poor prognosis. The aim of the present study was to identify markers for monitoring the response of 123 PROC patients enrolled in the Phase I/II GANNET53 clinical trial, which evaluated the efficacy of Ganetespib in combination with standard chemotherapy versus standard chemotherapy alone. In total, 474 blood samples were collected, comprising baseline samples taken before the first administration of the study drugs and serial samples taken during treatment until further disease progression (PD). After microfluidic enrichment, 27 gene transcripts were analyzed using quantitative polymerase chain reaction and their utility for disease monitoring was evaluated. At baseline, ERCC1 was associated with an increased risk of PD (hazard ratio [HR] 1.75, 95% confidence interval [CI]: 1.20–2.55; p = 0.005), while baseline CDH1 and ESR1 may have a risk‐reducing effect (CDH1 HR 0.66, 95% CI: 0.46–0.96; p = 0.024; ESR1 HR 0.58, 95% CI: 0.39–0.86; p = 0.002). ERCC1 was observed significantly more often (72.7% vs. 53.9%; p = 0.032) and ESR1 significantly less frequently (59.1% vs. 78.3%; p = 0.018) in blood samples taken at radiologically confirmed PD than at controlled disease. At any time during treatment, ERCC1‐presence and ESR1‐absence were associated with short PFS and with higher odds of PD within 6 months (odds ratio 12.77, 95% CI: 4.08–39.97; p < 0.001). Our study demonstrates the clinical relevance of ESR1 and ERCC1 and may encourage the analysis of liquid biopsy samples for the management of PROC patients.

News (Medical) associated with Ganetespib

16 May 2024

·www.biospace.com

Angle PLC Announces Study of Ovarian Cancer CTCs Using Parsortix

INDEPENDENT STUDY OF OVARIAN CANCER CTCS HARVESTED BY THE PARSORTIX SYSTEM HIGHLIGHTS POTENTIAL TO PREDICT PROGRESSION FREE SURVIVAL FOR DRUG TRIALS The study investigated 123 metastatic ovarian cancer patients over two and a half years using the Parsortix system to assess 474 longitudinal patient samples Downstream qPCR molecular analysis of the Parsortix harvest for ESR1 and ERCC1 genes may be an early predictor of progression free survival and cancer progression respectively GUILDFORD, SURREY / ACCESSWIRE / May 16, 2024 / ANGLE plc ("the Company") (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is delighted to announce the publication of a study using the Parsortix® system to identify markers present in CTCs harvested from metastatic mutant-p53 platinum-resistant ovarian cancer (PROC) patients. The study was conducted as an offshoot of the European multi-centre GANNET53 Phase II clinical trial (NCT02012192) funded by the EU 7th Framework Programme (Grant agreement ID: 602602). The study investigated the efficacy of ganetespib in combination with paclitaxel vs. paclitaxel alone. Patients were enrolled across 12 clinical centres in Germany, Belgium, France, and Austria. The translational study, which the research team believes is the largest study of CTCs in ovarian cancer (in terms of number of patient samples analysed), was conducted by researchers at the Medical University of Vienna, Austria. The study analysed a total of 474 blood samples collected from 123 PROC patients at baseline (i.e. prior to first administration of study drugs), and at multiple timepoints over a period of two and a half years during treatment until disease progression. A panel of 27 gene transcripts (RNA) was analysed on Parsortix-harvested CTCs using standard laboratory qPCR analysis. The authors identified two CTC-associated markers with potential prognostic value. ERCC1, a key gene of the DNA damage response pathway, was associated with an increased risk of disease progression and worse outcomes, whereas the presence of ESR1, a gene encoding oestrogen receptor alpha (ERα), was associated with a reduced progression risk. The presence of ESR1 transcripts together with concurrent absence of ERCC1 transcripts in CTC-enriched samples at baseline and during treatment cycles was found to be predictive of improved progression free survival (PFS). Whereas the presence of ERCCI transcripts and the absence of ESR1 transcripts at baseline and during treatment cycles indicated a 12.77× greater likelihood (odds ratio) of cancer progression. The analysis of these biomarkers has the potential to provide an early indication of PFS ahead of clinical trial results and suggests that CTC characterisation may be a valuable tool for pharma drug trials in the future. In addition, the authors conclude that molecular characterisation of CTCs before and during treatment has the potential to be a useful tool to monitor ovarian cancer patients and may provide further insights into the biology of this difficult to treat disease. According to clinicaltrials.gov there are 1,024 active interventional studies enrolling more than 825,000 participants in ovarian cancer. The study is published as a peer-reviewed journal article in the International Journal of Cancer and is available online at ANGLE Chief Scientific Officer, Karen Miller, commented: "We are pleased to share this peer-reviewed publication by the Medical University of Vienna and the European GANNET53 consortium. The paper demonstrates the potential utility of molecular characterisation of CTCs enriched using the Parsortix system in monitoring ovarian cancer patients throughout their treatment and during follow-up. The scale of this study, both in terms of numbers of patients and timescale of follow-up, is particularly important. It clearly demonstrates how use of the Parsortix system in cancer trials could in the future enable our pharma customers to gain an early understanding of how patients are responding to their drug." Ovarian cancer accounted for over 320,000 new cases of cancer, and over 200,000 deaths worldwide in 20221. Diagnosis often occurs at a later stage, and although patients often respond well to initial treatment with a platinum-based chemotherapy, many patients relapse and develop resistance to treatment2. 1. American Cancer Society. Global Cancer Facts & Figures 5th Edition. Atlanta: American Cancer Society; 2024 2. Zamwar UM, Anjankar AP. Aetiology, epidemiology, histopathology, classification, detailed evaluation, and treatment of ovarian cancer. Cureus. 2022; 14:e30561 ANGLE plc +44 (0) 1483 343434 Andrew Newland, Chief Executive Ian Griffiths, Finance Director Berenberg (NOMAD and Broker) Toby Flaux, Ciaran Walsh, Milo Bonser +44 (0) 20 3207 7800 FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US) +44 (0) 203 727 1000 +1 (212) 850 5624 For Research Use Only. Not for use in diagnostic procedures. For Frequently Used Terms, please see the Company's website on Notes for editors About ANGLE plc ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis. ANGLE's commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix® system, associated consumables and assays. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Over 90 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit . SOURCE: ANGLE plc View the original press release on accesswire.com

Phase 2Clinical Result

10 Mar 2021

·www.biospace.com

Aldeyra Therapeutics to Present at the OIS Dry Eye Innovation Showcase on March 11, 2021

March 10, 2021 13:00 UTC LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and Chief Executive Officer Todd C. Brady, M.D., Ph.D. will discuss the potential of reproxalap as a novel, rapid-onset first-line treatment for dry eye disease as part of the Ophthalmology Innovation Summit’s Dry Eye Disease Innovation Showcase, which will take place virtually on Thursday, March 11, 2021 from 1:00 p.m. to 4:00 p.m. ET. The event will include a market overview and company presentations as well as panel discussions featuring experts who will provide industry and clinical perspectives on the dry eye disease market. Registration is complimentary. To register, click here: About Aldeyra Therapeutics, Inc. Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead investigational compounds, reproxalap and ADX-629, target RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer. For more information, visit and follow us on LinkedIn, Facebook, and Twitter.

20 Jan 2021

·www.biospace.com

Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced the closing of its underwritten public offering of 7,868,421 shares of its common stock at a public offering price of $9.50 per share, including 1,026,315 additional shares of common stock sold pursuant to the full exercise of the underwriters’ option to purchase additional shares. All of the shares in the offering were sold by Aldeyra. The gross proceeds to Aldeyra following the underwriters’ exercise of their option to purchase additional shares, before deducting underwriting discounts and commissions and offering expenses, were approximately $74.7 million. Aldeyra anticipates using the net proceeds from the underwritten offering for the continued development of its lead compound, reproxalap, and its other product candidates, as well as for working capital, and other general corporate purposes. Jefferies LLC and SVB Leerink LLC acted as joint book-running managers for the offering. BTIG LLC and Oppenheimer & Co. Inc. acted as co-lead managers for the offering. The shares of common stock described above were offered by Aldeyra pursuant to a shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission (SEC) and declared effective by the SEC on July 27, 2018. A final prospectus supplement relating to and describing the terms of the offering was filed with the SEC on January 14, 2021, and is available on the SEC’s web site at . Copies of the final prospectus supplement and accompanying prospectus relating to these securities may also be obtained by sending a request to: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022, by telephone at 877-821-7388 or by email at Prospectus_Department@Jefferies.com, or from SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, Massachusetts 02110, by telephone at 1-800-808-7525, ext. 6132, or by email at syndicate@svbleerink.com. This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdictions. About Aldeyra Therapeutics, Inc. Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead investigational compounds, reproxalap and ADX-629, target RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer. Safe Harbor Statement This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including but not limited to statements regarding the anticipated use of the proceeds from Aldeyra’s public offering of common stock. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Aldeyra’s SEC filings, including but not limited to the risks that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Aldeyra’s Annual Report on Form 10-K for the year ended December 31, 2019 and Aldeyra’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 which are on the SEC and available on the SEC's website at . In addition to the risks described above and in Aldeyra’s other filings with the SEC, other unknown or unpredictable factors also could affect Aldeyra’s results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Aldeyra undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

100 Deals associated with Ganetespib

External Link

KEGG	Wiki	ATC	Drug Bank
D10126	-	-	DB12047

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Myelodysplastic Syndromes	Phase 3	GB	-	07 Jul 2014
Acute Myeloid Leukemia	Phase 3	DK	-	01 Jul 2014
Advanced Lung Non-Small Cell Carcinoma	Phase 3	US	Synta Pharmaceuticals Corp.	01 Apr 2013
Advanced Lung Non-Small Cell Carcinoma	Phase 3	AT	Synta Pharmaceuticals Corp.	01 Apr 2013
Advanced Lung Non-Small Cell Carcinoma	Phase 3	BE	Synta Pharmaceuticals Corp.	01 Apr 2013
Advanced Lung Non-Small Cell Carcinoma	Phase 3	BA	Synta Pharmaceuticals Corp.	01 Apr 2013
Advanced Lung Non-Small Cell Carcinoma	Phase 3	CA	Synta Pharmaceuticals Corp.	01 Apr 2013
Advanced Lung Non-Small Cell Carcinoma	Phase 3	HR	Synta Pharmaceuticals Corp.	01 Apr 2013
Advanced Lung Non-Small Cell Carcinoma	Phase 3	CZ	Synta Pharmaceuticals Corp.	01 Apr 2013
Advanced Lung Non-Small Cell Carcinoma	Phase 3	FR	Synta Pharmaceuticals Corp.	01 Apr 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01042379 (I-SPY2, Pubmed)	Phase 2	Breast Cancer Neoadjuvant	233	Ganetespib	syncoppvqt(spnofvphpa) = ayhlpnrisj hybytfvdef (nysqxwfwyz )	-	01 Dec 2022
				Standard NAC control	syncoppvqt(spnofvphpa) = jhbpkqrcls hybytfvdef (nysqxwfwyz )
NCT01042379 (I-SPY2, ASCO2022) Manual	Phase 2	Triple Negative Breast Cancer Neoadjuvant HER2 Negative \| ER Negative \| PR Negative	363	pembrolizumab (Immune+ TNBC)	fvxkzoaohv(urzougduvh) = hcjxzowtfo pqsghvagzf (aqjgdqeoap )	Positive	02 Jun 2022
				carboplatin (VC) (Immune+ TNBC)	fvxkzoaohv(urzougduvh) = mghfohlxcq pqsghvagzf (aqjgdqeoap )
NCT01167114 (Pubmed \| Invest New Drugs) Manual	Phase 2	Neoplasms Second line	26	Ganetespib	ceuidnbhnn(ubltyeczbr) = lbbufhorty lssiaxpmqy (fqgggiazrn ) View more	Negative	01 Oct 2020
NCT01590160 (MESO-02, Pubmed \| Clin Cancer Res) Manual	Phase 1	Malignant Pleural Mesothelioma	27	pemetrexed+cisplatin+carboplatin+Ganetespib	iepsdlnibj(flcorukkhm) = isyfopnwby rpuwaroglc (pxjjwcwboe ) View more	Positive	15 Sep 2020
NCT02008877 (SARC023, Pubmed) Manual	Phase 1/2	Sarcoma \| Neurofibrosarcoma	20	Sirolimus+Ganetespib (phase 1 ：refractory sarcoma)	ooxenrfuae(rbethhtula) = ompchaemoq btluubyikn (fivqbuztji )	Negative	30 Jan 2020
				Sirolimus+Ganetespib (phase 2 ： MPNST)	ooxenrfuae(rbethhtula) = uvpybloqzb btluubyikn (fivqbuztji )
NCT02012192 (GANNET53, Pubmed) Manual	Phase 1/2	Ovarian Epithelial Carcinoma	10	Paclitaxel+Ganetespib (cohort 1)	ibcktgbdvd(wnidactvhg) = gvzgpsuitm qdldolvpze (azwtrowfmv )	Positive	10 Sep 2019
				Paclitaxel+Ganetespib (cohorts 2 and 3)	ibcktgbdvd(wnidactvhg) = qovplrhxpz qdldolvpze (azwtrowfmv )
NCT02012192 (GANNET53, CTgov)	Phase 1/2	Primary Peritoneal High-Grade Serous Adenocarcinoma \| Platinum-Resistant Primary Peritoneal Carcinoma \| Ovarian Epithelial Carcinoma ... View more	133	Ganetespib+Paclitaxel (Ganetespib + Paclitaxel)	monskxjtep(pwstjzkdkd) = vnfsrqhjvp koamzvggsv (ttlinoyfia, lsusatfpnz - nbrfwwotik) View more	-	13 Aug 2019
				Paclitaxel (Paclitaxel)	monskxjtep(pwstjzkdkd) = ynthrcmvxj koamzvggsv (ttlinoyfia, bcwwcciagg - yjuhjjkhec) View more
NCT02008877 (SARC023, CTgov)	Phase 1/2	Neurofibrosarcoma	20	ganetespib+Sirolimus	vlkwermini(ezpadprlfi) = zcuzolkaev tndzbwzzmd (aebqowxznq, mactuowipe - apevdsneqv) View more	-	02 May 2019
NCT01560416 (CTgov)	Phase 2	Hormone receptor positive breast cancer	50	Fulvestrant (ARM A - Fulvestrant)	eozvethpth(cnbyjsscmw) = ivwxgmxsyb kxadbrykrp (dljmnvmpqc, elrkrmfwdr - mldaiijrbd) View more	-	03 Jan 2019
				Ganetespib+Fulvestrant (Arm B - Fulvestrant+Ganetespib)	eozvethpth(cnbyjsscmw) = cuxetqmxpu kxadbrykrp (dljmnvmpqc, nuivtkpeyc - dovzqmvobr) View more
NCT01200238 (Pubmed) Manual	Phase 2	Uveal Melanoma	17	ganetespib (cohort A)	patujkyabc(qhjvcgxopt) = whbrymzpvp glrsxzgrkg (yxrbhpflrx ) View more	Negative	01 Dec 2018
				ganetespib (cohort B)	patujkyabc(qhjvcgxopt) = cluadeeirl glrsxzgrkg (yxrbhpflrx ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis